Morgan Stanley Assumes Bicara Therapeutics Inc (BCAX) at Overweight

October 20, 2026 3:13 AM EDT Send to a Friend
Morgan Stanley analyst Sean Laaman assumes coverage on Bicara Therapeutics Inc (NASDAQ: BCAX) with a Overweight rating and a price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login